# Robert C. Doebele

Source: https://onco.cc/people/robert-doebele/  
OnCo record `robert-doebele` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lung cancer researcher who led the pooled analysis showing that entrectinib shrinks NTRK fusion-positive tumours of many kinds, and who studied how ROS1 and NTRK cancers escape targeted drugs.

## Summary

Robert Doebele was first author of the 2020 Lancet Oncology integrated analysis of the entrectinib trials in NTRK fusion-positive solid tumours, part of the evidence for the drug's tumour-agnostic approval. As a physician-scientist at the University of Colorado he described resistance mechanisms in ROS1- and NTRK-driven lung cancers and helped establish patient-derived models of oncogene-addicted cancers.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: lung; targeted-therapy
- Role: Thoracic oncologist and drug developer
- Specialisms: NTRK fusions; ROS1-positive lung cancer; Acquired resistance to kinase inhibitors

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [NTRK fusion-positive non-small-cell lung cancer](https://onco.cc/cancers/ntrk-fusion-nsclc/), [ROS1-positive non-small-cell lung cancer](https://onco.cc/cancers/ros1-positive-nsclc/)
- key papers: [Entrectinib in NTRK fusion-positive solid tumours: integrated analysis of three trials](https://onco.cc/key-papers/paper-doebele-entrectinib-ntrk-lancet-oncol-2020/)

---
JSON: https://onco.cc/api/v1/entities/robert-doebele.json